Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
Incyte (INCY) Stock Price & Analysis
1,529 Followers
INCY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$50.27 - $67.37
Previous Close$53.76
Volume153.29K
Average Volume (3M)1.89M
Market Cap
$12.08B
Enterprise Value$8.45B
Total Cash (Recent Filing)$3.66B
Total Debt (Recent Filing)$32.60M
Price to Earnings (P/E)16.3
Beta0.62
Next Earnings
Jul 30, 2024EPS Estimate
$1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding224,540,751
10 Day Avg. Volume2,400,675
30 Day Avg. Volume1,889,748
Standard Deviation0.08
R-Squared0.19
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.46
Price to Sales (P/S)11.91
Price to Cash Flow (P/CF)20.40
P/FCF Ratio20.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.37
Enterprise Value/Gross Profit2.46
Enterprise Value/Ebitda8.55
Forecast
1Y Price Target
$70.63Price Target Upside31.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Incyte News
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsOpzelura and povorcitinib demonstrate significant improvements in treating skin conditions, marking progress in Incyte's dermatology franchise.
Product DemandPaid demand for Jakafi increased to the highest levels since its launch.
Strategic AcquisitionsIncyte's acquisition of Escient Pharmaceuticals brings in clinical-stage assets with the potential to enrich its inflammation and autoimmunity portfolio.
Bears Say
Financial HealthIncyte's decreased cash position post-acquisition, now approximately $3 billion, influences the belief that shares are fairly valued.
Product PerformanceIncyte missed consensus on key product revenues, with Jakafi sales significantly underperforming expectations.
Research & DevelopmentManagement noted that modified clinical endpoints would likely be needed for ruxolitinib cream in HS, introducing additional uncertainty for the regulatory path forward.
---
Ownership Overview
30.68% Insiders
22.06% Mutual Funds
29.09% Other Institutional Investors
18.17% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $50.27 and its highest was $67.36 in the past 12 months.
What is Incyte Corp’s market cap?
Currently, no data Available
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Jul 30, 2024 which is in 83 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Apr 30, 2024. The company reported $0.643 earnings per share for the quarter, missing the consensus estimate of $0.798 by -$0.155.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is $1.07.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 224,540,760 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $0.643 in its last earnings report, missing expectations of $0.798. Following the earnings report the stock price went down -0.97%.
Which hedge fund is a major shareholder of Incyte Corp?
Among the largest hedge funds holding Incyte Corp’s share is Baker Bros Advisors LP. It holds Incyte Corp’s shares valued at 2B.
---
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$70.63 (31.23% Upside)
$70.63 (31.23% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 592.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.98%
12-Months-Change
Fundamentals
Return on Equity
15.13%
Trailing 12-Months
Asset Growth
23.08%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
---
INCY Company Deck
---
INCY Earnings Call
Q1 2024
0:00 / 0:00
---
INCY Revenue Breakdown
85.65% Product revenues, net
14.16% Product royalty revenues
0.19% Milestone and contract revenues
---
INCY Stock 12 Months Forecast
Average Price Target
$70.63
▲(31.23% Upside)
Technical Analysis
Best Analysts Covering INCY
1 Year
1 Year Success Rate
16/24 ratings generated profit
1 Year Average Return
+8.04%
reiterated a buy rating 7 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +8.04% per trade.
---